PACE-CME

Statin lowers CV risk, in absence of LDL-c measurement

Statin lowers CV risk in absence of LDLc measurement
RestartResume
    3' education - Apr. 28, 2016 - ACC 2016, Chicago - Jackie Bosch (Hamilton, ONT, Canada)
    • Overview

      Participants in the HOPE-3 study were recruited based on their CV risk, without requesting a baseline LDL-c measurement. In the intermediate risk population, randomisation to rosuvastatin yielded a 25% CV risk reduction. 

    Facebook Comments

    Register

    We’re glad to see you’re enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free